The Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving Liquidity
Go back to The Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving Liquidity| TARGETS Trust XXIV 7% TARGETS with respect to the common stock of Intel Corporation (NASDAQ: TOI) | Delayed: 5.07 -0.22 (4.16%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.29 | 52 Week High | $7.47 | |||
| Open | $5.21 | 52 Week Low | $7.47 | |||
| Day High | $5.25 | P/E | N/A | |||
| Day Low | $5.03 | EPS | $0.00 | |||
| Volume | 1,338,725 | |||||
| TARGETS Trust XXIV 7% TARGETS with respect to the common stock of Intel Corporation (NASDAQ: TOI) | Delayed: 5.07 -0.22 (4.16%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.29 | 52 Week High | $7.47 | |||
| Open | $5.21 | 52 Week Low | $7.47 | |||
| Day High | $5.25 | P/E | N/A | |||
| Day Low | $5.03 | EPS | $0.00 | |||
| Volume | 1,338,725 | |||||
